IRIS UniCatt

Bacigalupo, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.022
NA - Nord America 3.569
EU - Europa 2.714
SA - Sud America 1.025
AF - Africa 119
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.467
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.423
SG - Singapore 1.834
CN - Cina 1.146
BR - Brasile 830
SE - Svezia 668
IT - Italia 636
DE - Germania 309
FR - Francia 205
IE - Irlanda 190
VN - Vietnam 174
ID - Indonesia 173
TR - Turchia 150
IN - India 149
GB - Regno Unito 148
RU - Federazione Russa 109
FI - Finlandia 104
PL - Polonia 80
UA - Ucraina 73
CA - Canada 72
KR - Corea 71
AR - Argentina 69
IQ - Iraq 50
MX - Messico 50
JP - Giappone 46
HK - Hong Kong 43
BD - Bangladesh 40
NL - Olanda 35
ZA - Sudafrica 32
EC - Ecuador 29
AT - Austria 26
BE - Belgio 25
VE - Venezuela 24
ES - Italia 23
CI - Costa d'Avorio 20
CO - Colombia 20
CL - Cile 18
IR - Iran 17
CZ - Repubblica Ceca 16
UY - Uruguay 15
PK - Pakistan 14
AU - Australia 13
EG - Egitto 13
KE - Kenya 13
JO - Giordania 12
MA - Marocco 12
PY - Paraguay 11
UZ - Uzbekistan 11
SA - Arabia Saudita 9
DZ - Algeria 8
KZ - Kazakistan 7
LT - Lituania 7
RO - Romania 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
CH - Svizzera 6
IL - Israele 6
NP - Nepal 6
DK - Danimarca 5
KG - Kirghizistan 5
OM - Oman 5
PT - Portogallo 5
SN - Senegal 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
ET - Etiopia 4
GE - Georgia 4
LB - Libano 4
MD - Moldavia 4
PE - Perù 4
PH - Filippine 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
HR - Croazia 3
HU - Ungheria 3
JM - Giamaica 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BH - Bahrain 2
CR - Costa Rica 2
EU - Europa 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
LI - Liechtenstein 2
LK - Sri Lanka 2
MY - Malesia 2
NO - Norvegia 2
PR - Porto Rico 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
Totale 11.444
Salva come PNG Salva come JPEG
Città #
Singapore 786
Chandler 555
Ashburn 321
Beijing 211
Dublin 186
Hefei 182
Jakarta 158
Rome 128
Izmir 120
Ann Arbor 119
Los Angeles 119
Wilmington 106
Nanjing 98
Milan 94
New York 91
Dallas 87
São Paulo 79
San Mateo 74
Warsaw 72
Moscow 71
Jacksonville 69
Munich 69
Seoul 67
Fairfield 65
Boston 64
Ho Chi Minh City 63
Houston 63
Cattolica 56
Frankfurt am Main 54
Princeton 54
Kent 53
Nanchang 53
Chicago 52
Hyderabad 51
Florence 50
Seattle 45
Hanoi 39
Dearborn 38
Hong Kong 36
Lawrence 36
Redwood City 36
Helsinki 34
Marseille 34
Boardman 33
Tokyo 33
Woodbridge 33
Fuzhou 32
The Dalles 31
Paris 26
Brussels 24
Nuremberg 24
Hebei 23
Shanghai 23
Bremen 22
Kunming 22
Lancaster 22
Redmond 22
Santa Clara 22
Buffalo 21
Cambridge 21
Abidjan 20
Belo Horizonte 20
Jiaxing 20
Montreal 20
Shenyang 20
Atlanta 19
Guangzhou 19
Lappeenranta 19
Porto Alegre 19
Tianjin 19
Toronto 19
Changsha 18
Hangzhou 18
Phoenix 18
London 17
Mexico City 17
Brasília 16
Brooklyn 16
Mountain View 16
Pune 16
Rio de Janeiro 16
Denver 15
Dhaka 15
Curitiba 14
Johannesburg 14
San Francisco 14
Turku 14
Arezzo 13
Council Bluffs 13
Baghdad 12
Düsseldorf 12
Montevideo 12
Orem 12
Quito 12
Stockholm 12
Washington 12
Amman 11
Bologna 11
Brno 11
Manchester 11
Totale 5.894
Salva come PNG Salva come JPEG
Nome #
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 360
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies:uptade consensus recommendations of the European Society for Blood 276
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogenic stem cell transplantation: consensus-besed recommendations by an international expert panel 234
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 124
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 124
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 124
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 121
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 118
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 114
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 113
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 110
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 109
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 108
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 107
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 107
Unrelated cord blood transplantation and post-transplant cyclophosphamide 103
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 103
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 102
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 102
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 101
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 100
Nasopharynxkarzinom in einem europäischen Gebiet mit geringer Inzidenz: Eine prospektive Beobachtungsanalyse der Kopf- und Hals-Studiengruppe der Italienischen Gesellschaft für Radioonkologie (AIRO) 100
A closer look at permissive HLA mismatch 99
Severe cmv infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in a mantle cell lymphoma old patient 99
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 97
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 97
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation 97
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 96
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 95
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 95
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 94
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 93
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 93
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 92
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 92
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 91
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 89
Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management 88
Alternative donor transplants for severe aplastic anemia: current experience 88
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 88
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups 87
Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? 87
Antithymocyte globulin in the conditioning regimen: why not? 87
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant 87
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 87
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression 84
Unrelated cord blood transplantation and post-transplant cyclophosphamide 84
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial 83
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 83
Integrating transplantation with antibodies and genetically modified T-cell therapies 83
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 82
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 82
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 82
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 81
Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia 81
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: A retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 81
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 81
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 80
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 80
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 80
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT 80
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 80
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation 79
THE IMPACT OF EDUCATION ON PATIENTS' PSYCHOEMOTIONAL STATUS DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE PROSPECTIVE STUDY BY THE GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO 78
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 78
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 78
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 78
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 77
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 77
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 77
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 77
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 76
RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT 76
Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant 76
Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation 76
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 76
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT 75
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 75
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 74
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 74
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 74
PURLs: Light therapy for nonseasonal major depressive disorder? 74
Alternative donor transplants for severe aplastic anemia: Current experience 74
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. 74
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 74
Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention 73
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 73
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012 72
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 72
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 72
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 71
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 70
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 70
CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation 70
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation 68
Reducing infectious complications after allogeneic stem cell transplant 68
Second haploidentical stem cell transplantation for primary graft failure 68
Long-term survival in a patient with head and neck paraganglioma treated with tailored modalities for 20 years: a case report 66
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients 66
How I treat acquired aplastic anemia 65
Totale 9.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021230 0 0 0 0 0 37 18 9 60 24 65 17
2021/2022744 72 12 31 31 49 15 15 116 49 72 129 153
2022/20231.746 260 228 137 243 140 215 79 117 169 50 85 23
2023/20241.169 41 262 66 63 35 115 80 83 39 82 133 170
2024/20252.750 74 84 212 119 184 87 103 98 358 272 629 530
2025/20263.525 1.001 247 530 694 825 228 0 0 0 0 0 0
Totale 11.716